血清CEA、SF、β_2-MG RIA联合检测对肺癌诊断及疗效观察的临床价值  

COMBINED RADIOIMMUNOASSAY OF SERUM CEA, SF AND β 2 MG FOR CLINICAL DIAGNOSIS AND OBSERVATION OF LUNG CANCER

作　　者：赵荣庆 陈惠玲[1] 朱海明[1] 

机构地区：[1]河南省肿瘤医院

出　　处：《同位素》1997年第1期40-43,共4页Journal of Isotopes

摘　　要：用放射免疫分析法（ＲＩＡ）检测了１０９例肺癌患者（腺癌３５例、鳞癌３２例、小细胞癌４２例）及对照组３０例的血清ＣＥＡ、ＳＦ、β２－ＭＧ含量，并对２０例肺癌患者化疗前、后的含量变化进行比较。结果表明，肺癌组血清ＣＥＡ、ＳＦ、β２－ＭＧ含量显著高于对照组（Ｐ＜０．０１），其单检阳性率依次为５６．９％、７２．５％、４７．７％，而ＣＥＡ、ＳＦ、β２－ＭＧ联检阳性率可达９１．７％。化疗后肺癌患者β２－ＭＧ含量与化疗前自身对照无明显下降（Ｐ＞０．０５），而ＣＥＡ与ＳＦ则明显下降（Ｐ＜０．０１）。由此说明，上述三项指标联检对肺癌诊治具有重要的临床价值。The contents of the serum CEA, SF and β 2 MG for 109 cases of lung cancer (35 adenocarcinoma cases, 32 squamous cell carcinoma cases and 42 small cell carcinoma cases) and 30 normal controls are determined by RIA. The pre and post chemotherapeutic changes are observed for 20 cases of lung cancer. The results show that the value of serum CEA, SF and β 2 MG of the 109 cases is clearly over that of the normal controls( P <0.01) with the positive rates being 56.9%,72.5% and 47.7%, respectively. The positive rate of the combining assay can be as high as 91.7%. The post chemotherapeutic β 2 MG content of patients with lung cancer shows no apparent decline( P >0.05). However, their serum CEA and SF decline sharply( P <0.01). The above studies reveal that the combined RIA is of significant clinical value in the diagnosis of lung cancer.

关 键 词：癌胚抗原 铁蛋白 放射免疫分析 肺癌 

分 类 号：R730.45[医药卫生—肿瘤]